Timothy J Schlidt
Fondatore presso Palo Santo Inc
Posizioni attive di Timothy J Schlidt
Società | Posizione | Inizio | Fine |
---|---|---|---|
Bridge Investments LLC
Bridge Investments LLC Investment ManagersFinance Bridge Investments LLC (Bridge Investments) is a private equity and venture capital firm founded in 1998 by Robert Goldberg and Daniel Goldberg. The firm is headquartered in Chicago, Illinois. | Investitore di Private Equity | 01/05/2020 | - |
Palo Santo Inc
Palo Santo Inc Investment ManagersFinance Palo Santo Inc (Palo Santo) is a venture capital firm founded in 2005 by Timothy J Schlidt and Daniel L. Goldberg. The firm is headquartered in New York. | Fondatore | 01/05/2020 | - |
Investitore di Private Equity | 01/05/2020 | - | |
Tactogen, Inc.
Tactogen, Inc. Pharmaceuticals: MajorHealth Technology Tactogen, Inc. develops mental wellness medicines. The American company was founded in 2020 by Matthew Baggott and Luke A. Pustejovsky. Matthew Baggott has been the CEO since 2020. | Consulente / Consigliere | 01/12/2021 | - |
Ksana Health, Inc.
Ksana Health, Inc. Packaged SoftwareTechnology Services Ksana Health, Inc. is a mental health technology company based in Eugene, OR. Ksana Health aims to transform mental health care and research by translating tools and findings developed by the University of S Center for Digital Mental Health into digital products and services. Led by Dr. Nick Allen, a professor of clinical psychology, the company provides clients, practitioners, administrators, and researchers with digital tools that continuously measure behavioral health and offer personalized interventions to improve mental health. The company was founded in 2019 by Will Shortt and Nick Allen, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/08/2022 | - |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Direttore/Membro del Consiglio | 01/11/2021 | - |
Storia della carriera di Timothy J Schlidt
Precedenti posizioni note di Timothy J Schlidt
Società | Posizione | Inizio | Fine |
---|---|---|---|
Madison Dearborn Partners LLC
Madison Dearborn Partners LLC Investment ManagersFinance Madison Dearborn Partners LLC (Madison Dearborn Partners) is a private equity firm founded in 1992 by John A. Canning Jr., Paul J. Finnegan, Samuel M. Mencoff, Robin P. Selati, James N. Perry Jr. and Timothy P. Sullivan. The firm is headquartered in Chicago, Illinois. | Analista di Private Equity | 01/01/2017 | 01/08/2019 |
Palo Santo Investors-Qp LP | Fondatore | 01/05/2020 | - |
Formazione di Timothy J Schlidt
University of Wisconsin | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Private Equity Investor | 2 |
Founder | 2 |
Director/Board Member | 2 |
Settori
Finance | 4 |
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 7 |
---|---|
Madison Dearborn Partners LLC
Madison Dearborn Partners LLC Investment ManagersFinance Madison Dearborn Partners LLC (Madison Dearborn Partners) is a private equity firm founded in 1992 by John A. Canning Jr., Paul J. Finnegan, Samuel M. Mencoff, Robin P. Selati, James N. Perry Jr. and Timothy P. Sullivan. The firm is headquartered in Chicago, Illinois. | Finance |
Bridge Investments LLC
Bridge Investments LLC Investment ManagersFinance Bridge Investments LLC (Bridge Investments) is a private equity and venture capital firm founded in 1998 by Robert Goldberg and Daniel Goldberg. The firm is headquartered in Chicago, Illinois. | Finance |
Palo Santo Inc
Palo Santo Inc Investment ManagersFinance Palo Santo Inc (Palo Santo) is a venture capital firm founded in 2005 by Timothy J Schlidt and Daniel L. Goldberg. The firm is headquartered in New York. | Finance |
Palo Santo Investors-Qp LP | |
Tactogen, Inc.
Tactogen, Inc. Pharmaceuticals: MajorHealth Technology Tactogen, Inc. develops mental wellness medicines. The American company was founded in 2020 by Matthew Baggott and Luke A. Pustejovsky. Matthew Baggott has been the CEO since 2020. | Health Technology |
Ksana Health, Inc.
Ksana Health, Inc. Packaged SoftwareTechnology Services Ksana Health, Inc. is a mental health technology company based in Eugene, OR. Ksana Health aims to transform mental health care and research by translating tools and findings developed by the University of S Center for Digital Mental Health into digital products and services. Led by Dr. Nick Allen, a professor of clinical psychology, the company provides clients, practitioners, administrators, and researchers with digital tools that continuously measure behavioral health and offer personalized interventions to improve mental health. The company was founded in 2019 by Will Shortt and Nick Allen, who has been the CEO since incorporation. | Technology Services |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Health Technology |
- Borsa valori
- Insiders
- Timothy J Schlidt
- Esperienza